

CURRICULUM VITAE

John Richard Corboy, M.D.

**Professor of Neurology
Department of Neurology/Mail Stop B185
Academic Office 1
12631 East 17th Avenue/Room 5221
PO Box 6511
Aurora, CO 80045-2527**

**Office: (303) 724-2187
e-mail john.corboy@ucdenver.edu
FAX: (303) 724-0985**

Education:

1976	B.A., Anthropology, University of Pennsylvania, Philadelphia, PA
1978	M.A., Anthropology, UCLA, Los Angeles, CA
1985	M.D., University of Pennsylvania, Philadelphia, PA
1985-1986	Internship, Internal Medicine Hospital of the University of Pennsylvania Philadelphia, PA
1986-1989	Residency, Neurology Hospital of the University of Pennsylvania Philadelphia, PA
1989-1992	Postdoctoral Fellowship in Neurovirology The Johns Hopkins University, School of Medicine, Baltimore, MD

Academic Appointments

1992-1994	Assistant Professor, Department of Neurology, University of Minnesota
1994-2000	Assistant Professor, Department of Neurology, University of Colorado
2000-2006	Associate Professor, Department of Neurology, University of Colorado
2006-present	Professor, Department of Neurology, University of Colorado
1997-present	Director and Organizer of University of Colorado Multiple Sclerosis Center; 2009 Co-Director Rocky Mountain MS Center at

2009-present	University of Colorado Director, Rocky Mountain MS Center Tissue bank
Hospital Positions: 1992-94	University of Minnesota, and Minneapolis Veteran's Affairs Staff Neurologist
1994-present	University of Colorado Hospital, Staff Neurologist
1995-2013	Denver Health Medical Center, Consulting Neurologist
2000-2017	Denver Veteran's Affairs Medical Center, Staff Neurologist

Honors:

1985	Alpers Clinical Neurology Award, University of Pennsylvania, School of Medicine
1985	Alpha Omega Alpha, Medical School Honor Society
1987	Dinon Teaching Award, Hospital of the University of Pennsylvania
1997	National Multiple Sclerosis Society, Colorado Chapter, Corporate Achievers Award
1997-98	Department of Neurology, Excellence in Medical Student Teaching
2000	National Multiple Sclerosis Society, Colorado Chapter, Programs Volunteer of the Year
2003	National Multiple Sclerosis Society, Colorado Chapter, Healthcare Provider of the Year
2005	Elected to American Neurological Association
2006	Denver Health Medical Center, Volunteer Physician of the Year
2007-17	Best Doctors in America
2013	Best Doctors for Executives, ColoradoBiz Magazine 2013, annual edition
2013	Member of winning team (Angry Beards) in Neurobowl at AAN Annual Meeting, San Diego, March, 2013
2017	Hillel Panitch Lecture, University of Vermont, 2017
2018	John Whitaker Lecture, Paralyzed Veterans of America, Dallas, TX, August, 2018

Membership in Professional Organizations:

1989-1995	American Association for the Advancement of Science
1985-present	American Academy of Neurology, Fellow 2003
1993-1995	American Society for Microbiology
1994-present	Colorado Society of Clinical Neurologists 1995-1997 Secretary/Treasurer
2005-present	American Neurological Association, elected

Committees and Service Responsibilities:

Departmental	
1995 - 2001	Residency Program Director, Department of Neurology, University of Colorado Health Sciences Center

2000-2002	Vice Chairman, Dept. of Neurology, University of Colorado School of Medicine
2005	Committee on Faculty Call
2004-2006	Faculty Senator
2008-ongoing	UPI Incentive Committee (Chair)
2009-ongoing	Space committee (Co-Chair)
2010-ongoing	Clinic Improvement Committee (Ringel, Chair)
2010-ongoing	Residency Curriculum Committee (Miravalle, Chair)
2011-14	Hearts of All Ages Fundraising (Chair)
2014	eRVU Taskforce (Chair)
2015-present	Intradepartmental Grant Committee Origination (Chair)
2015-present	Director, Faculty Affairs; 2016 Vice Chair
2017-present	Vice Chair, Clinical Affairs
 School of Medicine	
1997	Search Committee for Director of Development, University of Colorado School of Medicine
1997 - 2001	Dean's Committee on Philanthropic Development, University of Colorado School of Medicine
2003	School of Medicine Curriculum Committee, Goals and Objectives Subcommittee
2006	General Clinical Research Center, ad hoc grant reviewer
2017-present	Clinical Leadership Council
 University of Colorado Hospital	
2002	Transmissible spongiform encephalopathy policy revision committee, University of Colorado Hospital
2008-ongoing	MS Section Co-Representative (with Dr. Vollmer)
 Denver Health Medical Center	
2001-2013	Unpaid Volunteer Physician at Bi-Monthly MS Clinic which I created
 State Committees	
1989-1992	National Multiple Sclerosis Society, Maryland Chapter, Professional Advisory Committee
1998 - 2017	National Multiple Sclerosis Society, Colorado Chapter, Clinical Advisory Committee
2005 - 2017	National Multiple Sclerosis Society, Colorado Chapter, Board Member
1999	Lupus Foundation of Colorado, Inc., Health Advisory Board, Neurology Advisor
2005	Cover Colorado, member of ad hoc committee on physical, occupational and speech therapy benefits for disabled patients
2014-2017	Patient Advocate to Medicaid P and T Committee on MS drugs; unpaid consultant to committee 2014

National

1997 - 2009	American Academy of Neurology, Education Committee Graduate Education Subcommittee, and A.B. Baker Committee on Education
2003-2009	American Academy of Neurology, Chairperson of Graduate Education Subcommittee
2005-2011	National Multiple Sclerosis Society, National Board, Committee on Professional Education
2009-2015	American Academy of Neurology, Meeting Management Committee
2015-16	AAN MS Section Economic Work Group
2017-present	AAN Science Committee

Other

2004-present	Alumni interviewer for undergraduate applicants to University of Pennsylvania
--------------	---

Medical Licensure:

Pennsylvania 1985-89
Maryland 1989-92
Minnesota 1992-94
Colorado 1994-present active

Board Certification:

October 1990	American Board of Psychiatry and Neurology (no re-certification required)
--------------	--

Review and Referee Work:

1992, 2004	Ad Hoc Reviewer, <i>Annals of Neurology</i>
1994-1997	Ad Hoc Reviewer, <i>International Journal of Neurological Sciences</i>
1998-2015	Ad Hoc Reviewer, <i>Archives of Neurology</i>
1999-2015	Ad Hoc Reviewer, <i>Journal of Neurologic Sciences</i>
1999-present	Ad Hoc Reviewer, <i>Neurology</i>
2001-2009	Section Editor, Neuroimmunology, <i>Current Treatment Options in Neurology</i>
2002	Ad Hoc Reviewer, <i>Experimental Neurology</i>
2002	Ad Hoc reviewer, <i>Journal of Clinical Epidemiology</i>
2003	Ad Hoc Reviewer, <i>Journal of Clinical Drug Investigation</i>
2005	Ad Hoc Reviewer, <i>Applied Neurology</i>
2005-present	Ad Hoc Reviewer, <i>Multiple Sclerosis</i>
2005-2008	Section Editor, Case in Point, <i>Neurology Today</i>
2006	Ad Hoc reviewer, <i>Current Medical Research and Opinion</i>
2007	Ad Hoc Reviewer, <i>Acta Neurologica Scandinavica</i>
2008	Ad Hoc reviewer, <i>European Journal of Neurology</i>

2009	Ad Hoc reviewer <i>Pharmacoepidemiology and Drug Safety</i>
2009-2011	Ad Hoc reviewer <i>Clinical Pharmacology and Therapeutics</i>
2010	Guest editor for <i>Neurology</i> supplement and potential new journal through AAN (Tentative title, <i>Clinical Practice Journal</i>). Two issues to date, through Spring, 2011.
2010	Grant Review, National MS Society, Chronic Cerebrospinal Venous Insufficiency Correlation Study in MS. NMSS offices, New York, New York; May 27, 2010
2011-present	Editor (Inaugural), <i>Neurology Clinical Practice</i> , a journal of the AAN
2016-present	Ad Hoc reviewer <i>Neurology and Therapy</i>
2016-present	Ad Hoc reviewer <i>Lancet, Neurology</i>
2017-present	Ad Hoc reviewer <i>Expert Review of Neurotherapeutics</i>
2018	Ad hoc reviewer, <i>JAMA</i>

Invited Lectures and Presentations:

1989-2005	Seminars with various Multiple Sclerosis support groups in Maryland and Colorado
1996	Continuing medical education, University of Colorado - Migraine Therapeutics, Estes Park, Spring 1996 - Migraine Therapeutics, University of Colorado Health Sciences Center, Fall 1996
1997	Promise and Progress in MS Treatment - 1997, National Video Teleconference, National MS Society
1997	Managing Multiple Sclerosis, Southeastern Colorado AHEC, 5/31/97
1997	Multiple Sclerosis Therapy, Poudre Valley Hospital, Fort Collins, Colorado 7/8/97
1998	Multiple Sclerosis, at New Patient Orientation for the Multiple Sclerosis Society of Colorado Springs, Colorado 1/23/98
1998	Multiple Sclerosis: Research Update at National Multiple Sclerosis Society, Denver branch 1/31/98
1998	Multiple Sclerosis: An overview at Symposium of "A multidisciplinary approach to Multiple Sclerosis" for the Centennial Area Health Education Center, Greeley, Colorado 2/20/98
1998	Multiple Sclerosis Research Update at "Adventures in Accessibility - National Multiple Sclerosis Society, Denver Chapter at Brown Palace Hotel 8/31/98
1998	Latest Treatment of Multiple Sclerosis, at CME, Neurology Update for the Primary Care Practitioner, at Given Institute, Aspen, CO 9/12/98

- 1998 Multiple Sclerosis Update for Patients, National Multiple Sclerosis Society, Grand Junction Chapter, Grand Junction, CO 9/19/98
- 1998 New Therapies in Multiple Sclerosis, Poudre Valley Hospital Teleconference, Fort Collins, CO 11/14/98
- 1999 Multiple Sclerosis, at new patient orientation for the National Multiple Sclerosis Society, Denver Chapter 2/6/99
- 1999 New Therapies in Multiple Sclerosis - Montrose/Delta AHEC March 4-5, 1999
- 1999 KHOW Radio, University Health Talk, Multiple Sclerosis 3/21/99
- 1999 Latest Treatment of Multiple Sclerosis, at CME, Neurology Update for the Primary Care Practitioner, at Given Institute, Aspen, CO 9/1/99
- 1999 Multiple Sclerosis, New patient orientation, Pueblo Chapter, NMSS, Pueblo, CO, 10/2/99
- 1999 MS in the new millenium, Seminar for patients, University of Colorado 10/12/99
- 1999 Case discussions, Invited speaker, Kaiser Permanente, Denver, CO, 10/21/99
- 2000 Patient seminars at five MS patient support groups, set up by NMSS, Denver Chapter
- 2000 Latest Treatment of Multiple Sclerosis, at CME, Neurology Update for the Primary Care Practitioner and Neurologists, at Given Institute, Aspen, CO 8/5/99
- 2000 Multiple Sclerosis, New patient orientation, Denver Chapter, NMSS, Denver, CO, 9/9/99
- 2000 Rationale for Early MS Therapy, Cheyenne, Wyoming, 11/4/00
- 2001 National MS Society, Denver Chapter, Phone-in seminar, 4/19/01
- 2001 American College of Veterinary Internal Medicine, Annual Meeting, Denver, CO, Update on MS, 5/24/01. Invited speaker
- 2001 Progress in Neurodegenerative Diseases, Jefferson Medical School, Philadelphia, PA, Novel Therapies in MS, 5/5/01. Invited Speaker.
- 2001 37th Annual Internal Medicine Program, YMCA of the Rockies Estes Park, CO, Update on MS, 7/13/01, Invited Speaker
- 2001 Current issues in MS therapy, 11/14/01, Salt Lake City, Utah
- 2001 Current issues in MS therapy, 11/15/01, Boise, ID
- 2002 The end of "Diagnose and Adios", Invited lecture at AAN, to Student Interest Group in Neurology, Denver, CO, 4/15/02
- 2002 What's new in MS, Denver Zoo, Patient Seminar, 12/6/02
- 2003 Living well with MS in the early years, sponsored by NMSS, Castle Rock, CO, 2/27/03
- 2003 Early Treatment of MS, sponsored by Biogen, Breckenridge, CO,

- 3/1/03
- 2003 Diagnosis and Management of MS, Family Practice CME, McKee Hospital, Loveland, CO, 3/14/03
- 2003 Neurology residency in 2002: Results of a residency survey. AAN, Platform presentation, Monday, March 31, 2003, Honolulu
- 2003 Update on MS, 49th Annual Family Practice Review, YMCA of the Rockies, 6/25/03, Estes Park, CO
- 2003 Diagnosis of MS, St. Joseph's Hospital, Denver, Colorado, 9/12/03
- 2003 Diagnosis and management of MS, 49th Annual Family Practice Review, University of Colorado School of Medicine, Denison Auditorium, 11/6/03.
- 2003 Diagnosis of MS. CME. St. Mary Corwin Hospital, Pueblo CO, 12/10/03.
- 2004 Diagnosis of MS. Grand Rounds, University of Colorado Department of Neurology, 1/14/04.
- 2004 Diagnosis of MS. CME. Lutheran Hospital, Denver, CO, 1/10/04.
- 2004 Diagnosis of MS, CME, Recent Advances in Neurology, Steamboat, CO, sponsored by University of North Texas Health Science Center, 3/12/04.
- 2004 Diagnosis of MS: Use of MRI and results of initial evaluation for MS at a University MS center, UT Southwestern Multiple Sclerosis Comprehensive Treatment Training Program, Dallas, TX, 6/3/04
- 2004 Experimental and novel therapies in MS, UT Southwestern Multiple Sclerosis Comprehensive Treatment Training Program, Dallas, TX, 6/4/04
- 2004 Pitfalls in the use of MRI in the diagnosis of MS, Beaumont Neuroscience Conference, Beaumont Hospital, Dublin, Ireland, 7/16/04
- 2004 Treatment Options for the Progressing MS Patient, Colorado Society of Clinical Neurologists, Denver, CO, 9/1/04
- 2004 Diagnosis of MS, St. Joseph's Hospital, Denver, Colorado, 10/8/04
- 2005 Monoclonal antibody treatment in MS, Colorado Society of Clinical Neurologists, Denver, Colorado, 1/26/05
- 2005 Update in clinical research in MS, patient seminar sponsored by UCMSC in conjunction with National MS Society, Nighthorse-Campbell building, Fitzsimons campus, 3/16/05
- 2005 Multiple Sclerosis Therapy, Course Director, AAN Annual Meeting, Miami, FL, 4/14/05
- 2005 Myths in Multiple Sclerosis, patient seminar sponsored by Teva, Denver Zoo, 7/20/05
- 2005 Relapses as an Outcome Measure in MS Clinical Trials, physician seminar, sponsored by Biogen, Marriot Hotel, Denver, CO, 8/6/05

2005 Diagnosis and detection of multiple sclerosis, Wardenburg Health Center, CME, University of Colorado Boulder Campus, 9/23/05

2005 Update in Multiple Sclerosis, Penrose Hospital Grand Rounds, Colorado Springs, CO, 9/29/05

2006 Multiple Sclerosis: Diagnosis and Management. St. Joseph's Hospital, Denver, CO, 1/1/12/06.

2006 Advances in MS. Lutheran Exempla Medical Center CME, March 21, 2006

2006 Diagnosis of MS: Role of MRI and differential diagnosis at a University MS center, UT Southwestern Multiple Sclerosis Comprehensive Treatment Training Program, Dallas, TX, 4/21/06

2006 Novel therapies in MS, UT Southwestern Multiple Sclerosis Comprehensive Treatment Training Program, Dallas, TX, 4/22/06

2006 Update on MS from the AAN, CME, Denver, CO, 4/12/06

2006 Practical issues in MS. Exempla Good Samaritan Medical Center, CME, Lafayette, CO. 8/03/06

2006 Research Advances in MS, Invited guest speaker, National MS Society, Colorado Chapter, Annual Meeting. Denver, CO 10/30/06

2006 Practical issues in MS. St. Joseph's Hospital, Denver, CO 11/10/06

2007 Research advances in MS, invited guest speaker, National MS Society, Colorado Chapter, Special fundraising seminar. Denver, CO 4/23/07

2007 Diagnosis and Treatment of MS. St. Joseph's Hospital, Denver, CO 10/19/07

2008 Advances In MS, Patient Seminar, 1/10/08, Denver, CO.

2008 B Cells in MS, Advances in MS and Parkinson's Disease, University of Colorado CME, 9/6/08, Inverness Hotel, Centennial, Colorado

2008 MS research, Patient seminar 10/2008, Denver, CO

2008 Diagnosis and Treatment of MS. St. Joseph's Hospital, Denver, CO 11/14/08

2009 Conversations in MS, Patient Seminar, July, 2009, Ft. Collins, CO

2009 Conversations in MS, Patient Seminar, August, 2009, Aspen, CO

2009 Erdheim-Chester Disease. Grand rounds, CU Neurology, 11/4/09

2009 Diagnosis and treatment of MS. St. Joseph's Hospital, Denver, CO. 11/13/09

2009 MS immunotherapy and beyond. U of Colorado CME, Inverness Hotel, Centennial, CO, 11/20/09

2009 Symptomatic and reparative therapies in MS. RMMSC Research in MS: Hype vs Hope. Aurora Summit Event Center, Aurora, CO 12/12/09.

2010 Cutting Edge 2010: Research Updates in MS. CME sponsored by

ProCE, Sullivan's Steakhouse, Denver, CO, 7/13/10

2010 Exercise as a Prescriptive Therapy in MS. Denver, Colorado, 10/2-3/10, Subgroup Leader. Sponsored by Consortium of MS Centers.

2010 Diagnosis and treatment of MS. St. Joseph's Hospital, Denver, CO. 11/12/10.

2010 Update on MS research, Patient support group, 1/2010, Denver, CO

2010 Recovery of Function in MS, Patient Seminar, Fort Collins, CO, 2/17/10

2010 American Academy of Neurology, Toronto, Canada, April 10-17. Lecturer in three courses:

1. Update in Neurology: Multiple Sclerosis
2. Morning report: Multiple Sclerosis
3. Multiple Sclerosis Cases – also Course Director

2011 Basic Neuroimmunology and Neuroimmunologic Disease, American Neuropsychiatric Association Annual Meeting, Denver, CO, 3/25/11

2011 Recovery Of Function in MS, Patient Seminar, Aurora, CO, 3/14/11

2011 American Academy of Neurology, Honolulu, HI, April 11, 2011 Multiple Sclerosis Cases; and Multiple Sclerosis Morning Report

2011 Cutting Edge 2011: Research Updates in MS, CME, Broadmoor Hotel, Colorado Springs, CO, 6/16/11

2011 8th Annual Johns Hopkins MS Symposium on Sept 17th, 2011, MS Cases. Washington DC.

2011 Update on MS. AAN Fall Conference, Las Vegas, NV, 10/21/11

2011 MS Cases. AAN Fall Conference, Las Vegas, NV, 10/22/11

2011 Updates from ECTRIMS, CME, Omaha, NE, 12/12/11

2012 MS Consensus 2012: From Research to Practice

1. CME Live, Centennial, CO 6/25/12
2. CME Webinar 10/16/12

2012 Paradigm Shifts in MS Therapy , Grand Rounds, University of Pennsylvania, Department of Neurology, 10/4/2012

2012 Scholarly Communication: Publishing in 2012, University of Colorado Anschutz Medical Campus, 10/18/2012

2012 Paradigm Shifts in MS Therapy, Patient Seminar, Aurora, CO 11/3/2012

2012 Paradigm Shifts in MS Therapy, Grand Rounds University of Rochester 12/14/12

2013 Paradigm Shifts in MS Therapy , 9th Annual Johns Hopkins MS Symposium, New York, NY, 1/12/13

2013 MS: A Neuroimmunological Disease, Regis College Senior Neuroscience seminar, 2/22/2013, with Robin Cloues, PhD

- 2013 RMMSC Living Well: Update on MS from the AAN, Westminster, CO ,5/11/13
- 2013 Changing Paradigms in MS Therapies, Potential Biomarkers, and the Advent of Personalized Medicine, Peer Review Live, Invited speaker at Consortium of MS Centers/ACTRIMS, Orlando, FL, 5/29/2013
- 2013 MS Update from the AAN, Prime CME, Palm Restaurant, Denver, CO, 6/4/2013
- 2013 Changing Treatment Algorithms in MS, VISN 19, Embassy Suites Denver Airport, 9/27/2013
- 2013 Update on MS; and Continuum Case Conference:MS, AAN Fall Conference, Las Vegas, NV, 10/25-27/2013
- 2013 Changing Paradigms in MS Therapies, Health South medical Directors Meeting, Nashville, TN, 11/3/2013
- 2013 Changing Paradigms in MS Therapies, National Association of Managed Care Physicians, Las Vegas, NV, 11/14/2013
- 2013 Changing Paradigms in MS Therapies, University of New Mexico, Dept of Neurology Grand Rounds, 12/6/2013
- 2014 Five New Things in MS. Grand Rounds, University of Colorado School of Medicine, Department of Neurology, 2/2014
- 2014 Changing Paradigms in MS Therapy. Novartis Headquarters, East Hanover, NJ. 4/2014
- 2014 Case Conference Discussion. The 10th Annual Johns Hopkins Multiple Sclerosis Series. Denver, CO. 11/1/2014
- 2015 Discontinuation of Disease Modifying Therapies in MS. University of Colorado Grand Rounds, 2/18/2015
- 2015 Discontinuation of Disease Modifying Therapies in MS. New York University, Langone Medical Center, Grand Rounds, 2/24/2015.
- 2015 Focusing Early, Seizing the Opportunity. Sponsored by Novartis (non-promotional). AAN, Washington, DC, 4/2015
- 2015 Tip of the Iceberg. Sponsored by Novartis (non-promotional). ECTRIMS, Barcelona, Spain 10/12/2015.
- 2016 Update from ECTRIMS. Palm Restaurant, Denver, Colorado. Sponsored by Prime CME. 1/12/2016
- 2016 MS Cases. AAN, Vancouver, Canada. 4/16/16
- 2016 Conversations in MS; Steamboat Springs, CO, library, 8/26/16
- 2016 Update on DMTs in MS. Spring Research Seminar. Rocky Mountain MS Center, Westminster, CO, 5/20/16; and Fall seminar, 10/29/16
- 2016 DISCOMS: When is it appropriate to discontinue disease modifying therapies in MS? PCORI National Meeting, Invited Speaker; Gaylord National Harbor Resort and Convention Center, 11/18/16

- 2017 Update from ECTRIMS. Palm Restaurant, Denver, Colorado. Sponsored by Prime CME. 1/10/2017
- 2017 MS through Lifetime. Invited speaker and organizer at AAN Breakthroughs Meeting, Phoenix AZ, 1/13/17
- 2017 Beyond DMTs for MS. Grand Rounds University of Colorado, Aurora, CO 3/15/17
- 2017 Should disease modifying therapies be stopped in progressive MS? YES (part of Pro-Con discussion). AAN Annual Meeting Invited Plenary Session, Boston MA, 4/27/2017.
- 2017 MS Cases. AAN Annual Meeting Invited Course Director, Boston, MA, 4/24/2017
- 2017 Conversations in MS, Patient Seminar Sponsored by the Rocky Mountain MS Center, Durango, CO. 8/18/17
- 2017 Conversations in MS, Patient Seminar Sponsored by the Rocky Mountain MS Center, Colorado Springs, CO. 9/28/2017
- 2017 Multiple Sclerosis Throughout a Lifetime. University of Vermont, Invited Grand Rounds speaker, Burlington VT, 10/13/17.
- 2017 Disease modifying therapy in the aging multiple sclerosis patient. Invited speaker, ECTRIMS/ACTRIMS Joint Meeting, Paris, France, 10/27/17
- 2018 Update from ECTRIMS 2017. Palm Restaurant, Denver, Colorado. Sponsored by Prime CME. 2/6/2018
- 2018 MS: Clinical Pearls. Invited Course Director and speaker. AAN Annual Meeting, Los Angeles, CA. April 2018
- 2018 Ask the Expert, Head Talk. Invited Speaker. AAN Annual Meeting, Los Angeles, CA. April 2018.
- 2018 MS Treatment Throughout Lifetime. Invited as John Whitaker Lecturer, Paralyzed Veterans of America Annual Conference. Dallas, Texas, August 28, 2018
- 2018 Conversations in MS; Colorado Springs, CO, library, 9/2018
- 2018 MS Treatment throughout lifetime. MSCoE Webinar. 9/11/18
https://www.va.gov/MS/Products/Audio_Archives/Audio_Archives.asp
- 2018 When to stop MS immunotherapy? ECTRIMS Invited Speaker. October 12, 2018. Berlin, Germany
- 2018 Update from ECTRIMS 2018. Palm Restaurant, Denver, Colorado. Sponsored by Prime CME. 11/27/2018
- 2019 Conversations in MS; Glenwood Springs, CO, library, 6/2019
- 2019 Risk Factors in Early MS. With Ian Shelton. Grand Rounds, University of Colorado School of Medicine, Neurology. Aurora, CO 8/21/2019
- 2019 Use of Disease Modifying Therapies in the Aging MS Patient. American Neurological Association. St. Louis, MO. 10/14/19

Teaching Record:

1992-94	Attending on wards eight weeks per year, University of Minnesota
1994-2017	Attending on wards 4-10 weeks per year, (UCH and DVAMC) with Neurology, Neurosurgery, Psychiatry and Internal Medicine Residents, and Medical Students, Bedside Teaching
1994-present	Annual Neurology Grand Rounds on various topics
1994-present	Annual Lecture to Neurology Residents and Medical Students on topics in Emergency Neurology.
1994-2017	School of Medicine, Medical Student Course, IDPT 6004, Annual Lectures on HIV in the nervous system (1994) and Multiple Sclerosis (1995-2017)
1996-present	Clinic Teaching Tuesday Afternoons in Multiple Sclerosis Clinic with Combinations of Neurology Residents and Medical Students
1997-2006	School of Medicine, Physical Medicine and Rehabilitation, Neuromuscular I DPTR6022, Physical Therapy Course, Annual Lecture on Multiple Sclerosis
1998-2002	School of Pharmacy, Integrated Organ Systems 4760, Annual Lecture on Multiple Sclerosis
1998-2010	Annual Journal Club for Neurology Residents at my home
2000-present	Foundations of Doctoring. Teaching of Neurological Examination to MS 2 Students
2001-present	Foundations of Doctoring. Mentor to Allen Scott Nielsen 2001-04 Mentor to Chris Lundberg 2005-09 Mentor to Zeljko Dvanajscak 2009-2015 Mentor to Brice McConnell 2009-12 Mentor to Mira Estin 2013-2017
2004-present	Twice Yearly Two-hour Didactics for Neurology residents and Medical Students on Rotating Topics In Inflammatory CNS Disorders, Wednesday Afternoon Neurology Seminars
2005	Course Director, Multiple Sclerosis Therapy, American Academy of Neurology, Annual Meeting, Miami, FL
2005-07	Molecules to Medicine, School of Medicine, Fall Semester
2006-09	Course Director, Multiple Sclerosis Cases, American Academy of Neurology, Annual Meeting, Various Locations
2010-2013	Multiple Sclerosis Case, American Academy of Neurology, Annual Meeting, Multiple Locations, Lecturer
2006	Annual lecture on MS to Physician's Assistant class, University of Colorado School of Medicine
2008	CME Course Co-Director (with Bette Demasters), Advances in MS and Parkinson's Disease, University of Colorado CME, Inverness

Hotel, Centennial, CO, 9/6/08, Inverness Hotel, Centennial, Colorado

2009 CME Course Director, Advances in MS, University of Colorado CME, Inverness Hotel, Centennial, CO, 11/20/09, Inverness Hotel, Centennial, Colorado

2010-13 American Academy of Neurology, Toronto (April, 2010) and Honolulu (April, 2011), New Orleans (2012), San Diego (2013)

2010 Course Director: Multiple Sclerosis Morning Report American Academy of Neurology, Toronto, Canada, April 10-17. Lecturer in three courses:

1. Update in Neurology: Multiple Sclerosis
2. Morning report: Multiple Sclerosis
3. Multiple Sclerosis Cases – also Course Director

2011 Basic Neuroimmunology and Neuroimmunologic Disease, American Neuropsychiatric Association Annual Meeting, Denver, CO, 3/25/11

2011 American Academy of Neurology, Honolulu, HI, April 11, 2011

2011 Multiple Sclerosis Cases; and Multiple Sclerosis Morning Report

2011 Cutting Edge 2011: Research Updates in MS, CME, Broadmoor Hotel, Colorado Springs, CO, 6/16/11

2011 MS Cases, 8th Annual Johns Hopkins MS Symposium on Sept 17th, 2011. Washington DC.

2011 Update on MS. AAN Fall Conference, Las Vegas, NV, 10/21/11

2011 MS Cases. AAN Fall Conference, Las Vegas, NV, 10/22/11

2011 Updates from ECTRIMS, CME, Omaha, NE, 12/12/11

2012 CME, University of Colorado, Paradigm Changes in MS Therapy, September, 2012, Inverness, Centennial, CO

2012 Paradigm Shifts in MS Therapy, Grand Rounds University of Colorado, 12/10/2012

2012 Update on MS for Primary Care, University of Rochester CME, 12/13/12

2013 Update on MS; and Continuum Case Conference, AAN Fall Conference, Las Vegas, NV, 10/25-27/2013

2016 Misdiagnosis of MS. AAN Plenary Session, April 2016. Vancouver, BC

2016 MS Cases. AAN annual Meeting, Vancouver, BC April 2016

2017 MS through Lifetime. Invited speaker and organizer at AAN Breakthroughs Meeting, Phoenix AZ, 1/13/17

2017 Beyond DMTs for MS. Grand Rounds University of Colorado, Aurora, CO 3/15/17

2018 MS: Clinical Pearls. AAN Annual Meeting Invited Course Director, Los Angeles, April, 2018

Grant Support:

CURRENT FUNDING

1. RISEMS Philanthropy 2018-2021 5% University time
Project Title: Risk Factors in Early MS (RISEMS). Role: PI
2. DISCOMS PCORI and NMSS 2017-2021 30% of University time
Project Title: Discontinuation of Disease Modifying Therapies in MS (DISCOMS).
Role: Site and Overall PI
3. Med Day Med Day 2016-2020 2% of University time
Project Title: Effect of MD1003 in progressive MS: a randomized double blind placebo controlled study. Role: PI
4. EXPAND Novartis 2013-2018 2% of University time
Project Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis. Role: PI
5. National MS Society 2009-continuing 15% of University time
Protocol Title: Rocky Mountain MS Center Tissue Bank Role: PI
6. ASSESS Novartis 2013-2018 2% of University time
Project Title: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis. Role: PI
7. Daclizumab HYP Biogen 2016-2018 Role: PI
I assumed the role of PI after the study was completed and in extension phase, as my colleague had moved to another university. My role was to complete the study and transition patients out of the study. I received no compensation for this work.

Recent Prior Funding

1. IMPACT Trial Biogen
Project Title: Avonex in secondary progressive MS 1998-2001 Role: PI
2. Simvastatin in MS
High dose oral simvastatin therapy in relapsing-remitting multiple sclerosis
2001-2004 Role: PI
3. ACT Biogen
Avonex Combination Trial 2005-2008 Role: PI
4. Uric acid and the Oxidative Stress of Exercise in Multiple Sclerosis. National MS Society, PI, \$33,167, 5% time. 2006-8
5. Magnetoencephalography in MS. Orasi Medical, PI, \$105,584 for 70 patients. 2008. 5% time. 2007-8
6. A Double-blind, Placebo Controlled Multi-center Study to Evaluate the Efficacy and

Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis. Protocol Number: BIO-MS, 2007-2010, Protocol MBP8298-SP-03. PI, \$258,059 direct costs, total \$300,208 for 10 patients, 5% time.

7. A Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with primary progressive multiple sclerosis. (U2786g Rituximab in Multiple Sclerosis). Genentech, 2005-2008, PI, \$247,317 for direct and indirect costs for 6 patients. 5% time. PI
8. CFTY720D2309 Novartis 2007-2010 5% \$1,562,816 direct and indirect costs Novartis Project Title: A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Role: PI
9. CombiRx- Phase III NIH 2005-2011 5% \$ 208,445 for 15 patients Protocol Title: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis Role: PI
10. Juvenile Diabetes Research Foundation 2008-2011 5% \$ 660,000 total costs Protocol Title: Common mechanisms of autoimmune disease Role: Co-PI
11. Lilly-H9B-MC-BCDJ 2010-2013 5% Project Title: Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing Remitting Multiple Sclerosis Role: PI
12. IT035A1 Immune Tolerance Network/NIAID 2010-2012 5% Project Title: A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults with Relapsing-remitting Multiple Sclerosis Role: PI
13. Celgene Therapeutics 2010-2012 5% Project title: A Phase IB, Randomized, Placebo Controlled, Multiple Dose Study to Evaluate the Safety of Intravenous Infusion of Cell Therapy (XXX) for the Treatment of Adults with Multiple Sclerosis Role:PI
14. CFTY720D2306 Novartis 2010-2014 2% Project Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis Role: PI
15. National MS Society 2009-14 10% Protocol Title: A Combination Trial of Copaxone plus Estriol in RRMS Role PI
16. Estriol/Cognition Private Philanthropy 2013-2016 5% of University time Effect of Estriol on cognition in MS patients Role:PI

Peer-Reviewed Publications:

1. Kreider BQ, **Corboy J**, et al. Characterization of Rat Schwannoma-Schwann Cell Hybrids. *Brain Research* 397:238-244, 1986.
2. **Corboy JR**, Fink L, Miller WT. Congestive Cardiomyopathy in Association with AIDS. *Radiology* 165:139-141, 1987.

3. **Corboy JR** and Galetta SL. Familial Cavernous Angiomas Manifesting with an Acute Chiasmal Syndrome. *Amer J Opth* 108:245-250, 1989.
4. **Corboy JR**, Buzy JM, Zink MC, Clements JE. Expression Directed from HIV Long Terminal Repeats in Central Nervous System of Transgenic Mice. *Science* 258:1804-1808, 1992.
5. **Corboy JR** and Garl, PJ. HIV-1 LTR DNA Sequence Variation in Brain-Derived Isolates. *J Neurovirol* 3:331-341, 1997.
6. **Corboy JR**, Garl PJ and Kleinschmidt-DeMasters BK. HHV-8 DNA in CNS Lymphomas from AIDS and Non-AIDS Patients. *Neurology* 50:335-340, 1998.
7. Singh M, **Corboy JR**, Stears JC and Kleinschmidt-DeMasters BK. Diffuse Leptomeningeal Gliomatosis Associated with Multifocal CNS Infarcts. *Surgical Neurology* 50:356-62, 1998.
8. Williamson, R.A., Burgoon, M.P., Owens, G.P., Ghausi, O., Leclerc, E., Firme, L., Carlson, S., **Corboy J**, Parren, P., Sanna, P.P., Gilden, D.H., Burton, D.R.: Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. *PNAS* 98:1793-1798, 2001.
9. Ross HL, Gartner S, McArthur JC, **Corboy JR**, McAllister JJ, Millhouse S, Wigdahl B. HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity. *J Neurovirol* 7(3):235-49, 2001.
10. Sapir, S., Pawlas, AA, Ramig, LO, Seeley, E, Fox, C, **Corboy JR**. Effect of intensive phonatory-respiratory treatment (LSVT) on voice in two individuals with multiple sclerosis. *J Medical Speech-Language Pathology* 9(2):141-151, 2001.
11. **Corboy JR**, Morgenlander, J., Rudnicki, S., Boudreau, E., Coyle, P.K.: Neurology Residency Programs at the Millenium. *Neurology* 58(10): 1454-60, 2002.
12. Nash RA, Bowen JD, McSweeney PA, Pavletic ZS, Maravilla KR, Park M-S, **Corboy JR**, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem transplantation in severe multiple sclerosis. *Blood* 102 (7): 2364-72, 2003.
13. Frohman EM, Goodin DS, Calabresi PA, **Corboy JR**, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH. The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 61(5):602-11, 2003.
14. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, **Corboy JR**, Gilden DH. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. *J Immunol*. 171(5):2725-33, 2003.
15. Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB Jr, Hogan N, Galetta S, Lee AG, Traumann D, Noseworthy J, Zee D, Corbett J, **Corboy J**, Rivera VM, Kramer PD. Accuracy of clinical detection of INO in MS: Corroboration with quantitative infrared oculoigraphy. *Neurology*. 61(6):848-850, 2003.
16. Vollmer, T.M., Key, L., Durkalski, V., Tyor, W., **Corboy J**, et al.: High dose oral simvastatin therapy in relapsing-remitting multiple sclerosis: an MRI study. *Lancet*,

- 363(9421):1607-8, 2004.
17. Ritchie AM, Gilden DH, Williamson RA, Burgoon MP, Yu X, Helm K, **Corboy JR** and Owens GP. Comparative Analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis, *J Immuno*, 173:649-56, 2004.
 18. Coombs BD, Best A, Brown MS, Miller DE, **Corboy J**, Baier M, Simon JH. Multiple Sclerosis Pathology in the Normal and Abnormal Appearing White Matter of the Corpus Callosum by Diffusion Tensor Imaging. *Multiple Sclerosis*, 2004;10:392-397.
 19. Carmosino MJ, Brousseau KM, Arciniegas DB, **Corboy JR**. Initial evaluations for multiple sclerosis in a university multiple sclerosis center: Outcomes and the role of magnetic resonance imaging in referral. *Arch Neurol*. 2005; 62: 585-590.
 20. Rollins KE, Kleinschmidt-Demasters BK, **Corboy JR**, Damek DM, Filley CM. Lymphomatosis cerebri as a cause of white matter dementia. *Hum Pathol*. 2005 Mar;36(3):282-90.
 21. Frohman EM, Filippi M, Stuve O, Waxman SG, **Corboy J**, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future direction *Arch Neurol*. 2005 Sep;62(9):1345-56.
 22. Frohman EM, Stuve O, Havrdova E, **Corboy J**, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Evidence, Experience, and Future Expectations. *Arch Neurol*. 2005;62:1519-1530.
 23. Frohman EM, Hardova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, **Corboy J**, Raine C, Cutter G, Richert J, Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. *Arch Neurol*. 2006 Apr;63(4):614-9.
 24. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, **Corboy JR** and Lennon VA . Neuromyelitis optica brain lesions colocalize at sites of high aquaporin-4 expression. *Arch Neurol*. 2006, 63(7):964-8.
 25. Hudson LA, Bernard TJ, Tseng BS, Miller BR, **Corboy JR**. Neuromyelitis optica Immunoglobulin G in a child. *Pediatric Neurology*, 2006;35(5):370-2.
 26. Adair JC, Rudnicki SA, Boudreau E, Weiner, MD WJ, Coyle PK, **Corboy JR**. Survey of training programs' means for promoting neurology and attracting trainees. *Neurology*, 2006;67(6):936-9.
 27. **Corboy JR**, Gault J, Kleinschmidt-Demasters BK. An Adult Case of Leukoencephalopathy with Intracranial Calcifications and Cysts. *Neurology*, 2006;67(10):1890-2.
 28. Tyor WR, Singh I, Vollmer T, Key L, **Corboy JR**, et al. The use of statins in multiple sclerosis. *Intl J of Multiple Sclerosis*, 2006; 8:10-12.
 29. Brousseau KB, Arciniegas D, **Corboy JR**. The Differential Diagnosis of Axis I Psychopathology Presenting to a University-Based Multiple Sclerosis Clinic. *Multiple*

- Sclerosis*, 2007 Jul;13(6):749-753. Epub 2007 Mar 15.
30. Simon, JH, Zhang S, Laidlaw DH, Miller DE, Brown M, **Corboy J**, Bennett J. Identification of fibers at risk for degeneration by diffusion tractography in patients at high risk for MS after a clinically isolated syndrome. *J Magn Reson Imaging*. 2006 Nov;24(5):983-8.
 31. Gill DG, Freeman WD, Thoresen P, **Corboy JR**. Residency Training: The neurology resident case log: A national survey of neurology residents. *Neurology* 2007;68: E32-E33
 32. LaFosse JM, **Corboy JR**, Leehey MA, Seeberger LC, Filley, CM. MS vs HD: Can white matter and subcortical gray matter pathology be distinguished neuropsychologically?. *J Clin and Experim Neuropsych*. 2007; 29(2):142-54.
 33. Owens GP, Wings KM, Ritchie AM, Edwards S, Burgoon MP, Lehnhoff L, Nielsen K, **Corboy J**, Gilden DH and Bennett JL. VH4 Gene Segments Dominate the Intrathecal Humoral Immune Response in MS *J Immunol*. 2007; 179:6343-51.
 34. Amaria RN, **Corboy JR**, Finlayson CA, Robinson WA, Borges VF. Immunomodulatory therapy in multiple sclerosis and breast cancer risk: A case report and literature review. *Clinical Breast Cancer* 2008; 8(5):449-52.
 35. Schuh L, Adair JC, Drogan O, Kissela BM, Morgenlander JC, **Corboy JR**. Neurology Residency Training in the new millennium. *Neurology* 2009;72:e15-e20/./.
 36. Kleinschmidt-DeMasters BK, Cummings TJ, Hulette CM, Morgenlander JC, **Corboy JR**. Adult cases of leukoencephalopathy, cerebral calcifications and cysts: expanding the spectrum of the disorder. *J Neuropathol Exper Neu* 2009; 68(4): 432-439.
 37. Butler M, **Corboy JR**, and Filley CM. How the conflict between American Psychiatry and Neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis. *Neuropsychology Review* 2009; 19(3): 399-410.
 38. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, **Corboy J**, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stüve O, Racke M, Frohman EM. Factors that influence adherence with disease-modifying therapy in MS. *J Neurol*. 2009 Apr;256(4):568-76. Epub 2009 Apr 27.
 39. Haug A, Mahalingam R, Cohrs RJ, Schmid DS, **Corboy JR**, Gilden D. Recurrent polymorphonuclear pleocytosis with increased red blood cells caused by varicella zoster virus infection of the central nervous system. *Journal of the Neurological Sciences*: 19-FEB-2010 DOI information: 10.1016/j.jns.2010.01.019
 40. Miravalle A and **Corboy JR**. Five new things in multiple sclerosis. *Neurology: Clinical Practice*, 2010 Nov 2;75(18 Suppl 1):S22-7.
 41. **Corboy JR**, Miravalle AA. Emerging therapies for treatment of multiple sclerosis. *J Inflamm Res*. 2010 2010:3 53–59.
 42. Freeman WD, Nolte CM, Matthew BR, Coleman C, and **Corboy JR**. Results of the American Academy of Neurology Resident Survey. *Neurology*. 2011 Mar 29;76(13):e61-7.

43. Hebert JR, **Corboy JR**, Manago MM, Schenkman M. Effects of Vestibular Rehabilitation on Multiple Sclerosis–Related Fatigue and Upright Postural Control: A Randomized Controlled Trial. *Physical Therapy*, 2011; 98:1-18
44. Nair KV, **Corboy J**, Kahler K, Allen R, et al. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. *Expert Rev. Neurother*, 2011; 11(6): 787–798.
45. Schowinsky J, **Corboy J**, Vollmer T, Kleinschmidt-Demasters BK. Natalizumab-associated complication? First case of peripheral T cell lymphoma. *Acta Neuropathol*. 2012 May;123(5):751-2. Epub 2012 Mar 11.
46. Kleinschmidt-Demasters BK, Miravalle A, Schowinsky J, **Corboy J**, Vollmer T. Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab. *J Neuropathol Exp Neurol*. 2012 Jul;71(7):604-17.
47. Campbell JD, McQueen RB, Miravalle A, **Corboy J**, Vollmer T, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus negative relapsing-remitting multiple sclerosis. *American Journal of Managed Care*, 2013; 19(4): 278-285.
48. Hebert JR, **Corboy JR**. The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration. *Gait Posture*. 2013 May;38(1):37-42. doi: 10.1016/j.gaitpost.2012.10.015. Epub 2012 Nov 28.
49. Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Livingston T, Vollmer T, **Corboy J**, Miravalle A, Schreiner T, Porter V, Nair KV. Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates. *Multiple Sclerosis and Related Disorders*. 2014; 3(2): 227-236. doi: 10.1016/j.msard.2013.09.004. Epub 2013 Nov 2
50. Lafosse JM, Mitchell SM, **Corboy JR**, Filley CM. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. *J Int Neuropsychol Soc*. 2013 Oct;19(9):995-1008. doi: 10.1017/S1355617713000957
51. Waid DM, Schreiner T, Vaitaitis G, Carter JR, **Corboy JR**, Wagner DH Jr. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. *J Neuroimmunol*. 2014 Mar 15. pii: S0165-5728(14)00073-3. doi: 10.1016/j.jneuroim.2014.03.009. [Epub ahead of print]
52. Larsen DP, Butler AC, Aung WY, **Corboy JR**, Friedman DI, and Sperling MR. The effects of test-enhanced learning on long-term retention in AAN annual meeting courses. *Neurology*. 2015 Feb 17;84(7):748-54. doi: 10.1212/WNL.0000000000001264. Epub 2015 Jan 21.
53. McQueen R, Livingston T, Vollmer T, **Corboy J**, Buckley B, Allen R, Nair K, and Campbell J. Increased relapse activity for multiple sclerosis natalizumab users who become non-persistent: a retrospective study. *J Manag Care Spec Pharm*. 2015 Mar;21(3):210-8b
54. Lublin FD, Bowen JD, Huddleston J, Kremenchutzky M, Carpenter A, **Corboy JR**, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study. *Multiple Sclerosis and Related Disorders* Volume 3,

55. Solomon AJ, Klein EP, **Corboy JR**, Bernat JL. Patient Perspectives on Physician Conflict of Interest in Industry-Sponsored Clinical Trials for Multiple Sclerosis Therapeutics. *Mult Scler*. 2015 Feb 25. pii: 1352458515569101. [Epub ahead of print].
56. Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, **Corboy JR**, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. *Lancet Neurol*. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29. PMID:26621682
57. Dilokthornsakul P, Valuck RJ, Nair KV, **Corboy JR**, Allen R, and Campbell JD. Multiple Sclerosis Prevalence in the United States Commercially Insured Population. *Neurology*. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.
58. Blakeley JO, Coons SJ, **Corboy JR**, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. *Neurology*. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.
59. Klein E, Solomon AJ, **Corboy J**, Bernat J. Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust. *Mult Scler Relat Disord*. 2016 Jul;8:4-8. doi: 10.1016/j.msard.2016.04.001. Epub 2016 Apr 11
60. Kister I, **Corboy JR**. Reducing costs while enhancing quality of care in MS. *Neurology*. 2016 Oct 11;87(15):1617-1622. doi: 10.1212/WNL.0000000000003113. [Epub ahead of print] PMID:27590294
61. **Corboy JR**. Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - Commentary. *Mult Scler*. 2017 Jun 1:1352458517717809. doi: 10.1177/1352458517717809. [Epub ahead of print] No abstract available. PMID: 28673113
62. Hardy TA, **Corboy JR**, Weinshenker BG. Baló concentric sclerosis evolving from apparent tumefactive demyelination. *Neurology*. 2017 May 30;88(22):2150-2152. doi: 10.1212/WNL.0000000000003990. Epub 2017 May 3. No abstract available. PMID: 28468846
63. Vollmer B, Nair KV, Sillau SH, **Corboy J**, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. *Mult Scler J Exp Transl Clin*. 2017 Aug 17;3(3):2055217317725102. doi: 10.1177/2055217317725102. eCollection 2017 Jul-Sep. PMID: 28839949
64. Solomon AJ, **Corboy JR**. The tension between early diagnosis and misdiagnosis of multiple sclerosis. *Nat Rev Neurol*. 2017 Sep;13(9):567-572. doi:10.1038/nrneurol.2017.106. Epub 2017 Aug 11. Review. No abstract available. PMID: 28799551.

65. Hassani A, **Corboy JR**, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. *PLoS One*. 2018 Feb 2;13(2):e0192109. doi: 10.1371/journal.pone.0192109. eCollection 2018.
66. Hebert JR, **Corboy JR**, Vollmer T, Forster JE, Schenkman M. Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS). *Neurology*. 2018 Feb 27;90(9):e797-e807. doi: 10.1212/WNL.0000000000005013. Epub 2018 Jan 31. PMID: 29386274.
67. **Corboy JR**, Weinshenker BG, Wingerchuk DM. Comment on the 2018 American Academy of Neurology guidelines on disease-modifying therapies in multiple sclerosis. Published electronically ahead of print, *Neurology*. 2018 Jun 12;90(24):1106-1112. pii: 10.1212/WNL.0000000000005574. doi: 10.1212/WNL.0000000000005574. [Epub ahead of print] Review. PMID: 29685920
68. Vollmer B, Honce JM, Sillau S, **Corboy JR**, Vollmer T, Nair K, Alvarez E. The Impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. *J Neurol Sci*. 2018 Jul 15;390:89-93. PMID:29801915
69. Gould JR, Reineberg AE, Cleland BT, Knoblauch KE, Clinton GK, Banich MT, **Corboy JR**, Enoka RM. Adjustments in Torque Steadiness During Fatiguing Contractions Are Inversely Correlated With IQ in Persons With Multiple Sclerosis. *Front Physiol*. 2018 Oct 17;9:1404. doi: 10.3389/fphys.2018.01404. eCollection 2018. PMID: 30386250
70. Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel, RA, **Corboy JR**, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. *Neurol Clin Pract*. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487. PMID: 30140580
71. Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, **Corboy JR**, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous hematopoietic stem cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2019 Feb 19. pii: S1083-8791(19)30139-9. doi: 10.1016/j.bbmt.2019.02.014. [Epub ahead of print]
72. Vollmer BL, Nair KV, Sillau S, **Corboy JR**, Vollemr T, Alvarez T. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. *Annals of Clinical and Translational Neurology* 2019; 6: pp
73. Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, **Corboy JR**, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. *Neurology*. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11. PMID: 30635477

74. Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, **Corboy JR**, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. *Mult Scler Relat Disord*. 2019 Sep 17;36:101402. doi: 10.1016/j.msard.2019.101402. [Epub ahead of print. PMID: 31542710]
75. McGinley MP, Cola PA, Fox RJ, Cohen JA, **Corboy JR**, Miller D. Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. *Mult Scler*. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314. [Epub ahead of print. PMID: 31368401]

Publications as Contributing Investigator:

1. Cohen JA, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. *Neurology*. 2002 Sep 10;59(5):679-87.
2. Cohen JA, et al. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. *Mult Scler*. 2008; 14:370-82.
3. Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. *Neurology*. 2009 Feb 10;72(6):535-41.
4. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. *Ann Neurol*. 2009 Oct;66(4):460-71.
5. Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL; Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. *J Child Neurol*. 2011 Jun;26(6):675-82. Epub 2011 Apr 25.
6. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS; CombiRx Investigators. Combining interferon and glatiramer acetate in MS. *Annals of Neurology* 2013; 73(3): 327-340.
7. Datta S, Staewen TD, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston; CombiRx Investigators Group. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data. *Mult Scler Relat Disord*. 2015 Mar;4(2):124-36. doi: 10.1016/j.msard.2015.01.004. Epub 2015 Jan 17.
8. Govindarajan KA, Datta S, Hasan KM, Choi S, Rahbar MH, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston, The

- CombiRx Investigators Group. Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study. *Hum Brain Mapp.* 2015 Oct;36(10):3749-60. doi: 10.1002/hbm.22875. Epub 2015 Jun 19. PMID:26096844
9. Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet.* 2016 Jan 27. pii: S0140-6736(15)01314-8. doi: 10.1016/S0140-6736(15)01314-8.
 10. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive **multiple sclerosis** (EXPAND): a double-blind, randomised, phase 3 study. *Lancet.* 2018 Mar 31; 391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. PMID: 29576505

Invited Publications, Editorials, Commentaries:

1. **Corboy JR**, Price RW. Myelitis and Toxic, Inflammatory and Infectious Disorders. *Curr Neurol Neurosurg* 6:564-570, 1993.
2. **Corboy JR**. Mitoxantrone: The new drug in the MS fight. *Managing MS* 1:2, 2001.
3. **Corboy JR**. Cognitive Problems in MS. *Managing MS* II(I): 3, November, 2001
4. **Corboy JR**, Goodin DS, Frohman EM. Disease-modifying Therapies for Multiple Sclerosis. *Curr Treat Options Neurol* Jan;5(1):35-54, 2003.
5. **Corboy JR**. Neurosarcoidosis. Case in Point, *Neurology Today*, March, 2006.
6. **Corboy John R** and Elkind Mitchell SV. Maintenance of certification: Ready or not, here it comes. *Neurology*, 2008;71 544-545.
7. **Corboy John R**. Chronic care in crisis: Why we need a new system. *Neurology Today*, 2008, June 19, pages 5-6.
8. Nielsen AS and **Corboy JR**. Typical MS in atypical patients. *Practical Neurology*, 2009
9. **Corboy JR**. Antibodies to Epstein-Barr Virus and MRI Disease Activity in MS. PracticeUpdate website. Available at: <http://www.practiceupdate.com/journalscan/10517>. Accessed July 14, 2014.
10. **Corboy JR**. Multiple Sclerosis Patients Have Increased ICU Admission and 1-Year Mortality. PracticeUpdate website. Available at: <http://www.practiceupdate.com/journalscan/10508>. Accessed July 14, 2014.
11. **Corboy JR**. Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions. PracticeUpdate website. Available at: <http://www.practiceupdate.com/journalscan/10523>. Accessed July 14, 2014.
12. **Corboy JR**. The relationship between physicians and Pharma: Playing the devil's advocate. *Neurol Clin Pract.* 2014 Apr;4(2):161-163.
13. Gross R and **Corboy JR** Monitoring, Switching and Discontinuing DMTs in Relapsing

MS. *Continuum* (Minneap Minn). 2019 Jun;25(3):715-735. doi: 10.1212/CON.0000000000000738. Erratum in: *Continuum* (Minneap Minn). 2019 Aug;25(4):1175. PMID: 31162313

14. Mowry EM, **Corboy JR**. Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. *Lancet Neurol*. 2019 Sep 3. pii: S1474-4422(19)30333-3. doi: 10.1016/S1474-4422(19)30333-3. [Epub ahead of print] No abstract available. PMID: 31492653

Book Chapters:

1. **Corboy JR**, Worley JM. Slow Infections of the Nervous System. In Jordan MC, Hoepfich PO, Ronald AL (eds): *Infectious Diseases: A Modern Treatise of Infectious Processes*. 5th edition, 110-1106, 1994.
2. **Corboy JR** and Tyler KL. *Neurovirology, in Neurology In Clinical Practice, 3/e*. Edited by: Drs. Walter Bradley, Robert Daroff, Gerald Fenichel, and C. David Marsden, Butterworth Heiemann, 823-40, 1999.
3. **Corboy JR** and Johnson, S. HIV in the Nervous System, *Encyclopedia of the Neurological Sciences*, Academic Press, 2003, 66-76, 2003.
4. Schabbing, R. and **Corboy JR**.: Viral illnesses in the nervous system of the elderly, in *Clinical Neurology of the Older Adult*, ed Joseph Sirven JI and Malamut BL. Lipincott, Williams and Wilkins pp. 363-371, 2002 .
5. Bainbridge, JL, **Corboy JR**, and Gidal, BE. Multiple Sclerosis, in *Pharmacotherapy, A Pathophysiologic Approach*, Fifth Edition, ed JT DiPiro, et al, McGraw Hill, 1019-30. , 2002.
6. Fuller K, **Corboy J** and Winkler P: Degenerative Diseases of the Central Nervous System, In *Pathology: Implications for the Physical Therapist*. 2nd ed., Ed Goodman C, Boissionnalt B and Fuller K, Elsevier, Philadelphia. pp 1022-1053. 2003.
7. **Corboy JR** and Tyler KL. Neurovirology, in *Neurology In Clinical Practice, 4/e*. Edited by: Drs. Walter Bradley, Robert Daroff, Gerald Fenichel, and C. David Marsden, Butterworth Heiemann, pp. 823-40, 2004.
8. Bainbridge, JL and **Corboy JR**. Multiple Sclerosis, in *Pharmacotherapy, A Pathophysiologic Approach*, Sixth Edition, ed JT DiPiro, et al, McGraw-Hill, pp. 1007-21, 2005.
9. **Corboy JR**, Rollins K. Multiple Sclerosis, in *McGraw-Hill Yearbook of Science and Technology, 2007*. McGraw-Hill, pp. 154-156.
10. Bainbridge JL and **Corboy JR**. Multiple Sclerosis, in *Pharmacotherapy, A Pathophysiologic Approach*, Seventh Edition, ed JT DiPiro, et al, McGraw-Hill, 2008.
11. Nagel M. and **Corboy JR**.: Viral illnesses in the nervous system of the elderly, in *Clinical Neurology of the Older Adult*, ed Joseph Sirven JI and Malamut BL. Lipincott, Williams Wilkins, 2008.
12. Bainbridge JL and **Corboy JR**. Multiple Sclerosis, in *Pharmacotherapy, A*

Pathophysiologic Approach, Eighth Edition, ed JT DiPiro, et al, McGraw-Hill, 2011 pp 963-978

13. Bainbridge JL, Miravalle A, and **Corboy JR**. Multiple Sclerosis, in *Pharmacotherapy, A Pathophysiologic Approach*, Ninth Edition, ed JT DiPiro, et al, McGraw-Hill, 2014 pp 835-854.

Letters, Other

1. **Corboy JR**. [CD4+ T-lymphocytopenia without HIV infection](#). *N Engl J Med*. 1993 Jun 24;328(25):1849; author reply 1849-50.
2. **Corboy JR**. [Physician-assisted suicide](#). *N Engl J Med*. 1997 Feb 6;336(6):439; author reply 440-1.
3. **Corboy JR**. [Patent foramen ovale, atrial septal aneurysm, and recurrent stroke](#). *N Engl J Med*. 2002 Apr 25;346(17):1331-2; author reply 1331-2
4. Multiple authors. Clinical trials: Solving one piece of the puzzle. North American Education Program. NMSS, 2009
5. Continuum Audio, Volume I, Issue 26, Special Inaugural Issue, Part II. Update in MS, interview with Ralph Jozefowicz, 2012
6. The future of scholarly communications and the health sciences industry. Panel Member. University of Colorado, Anschutz Medical Campus, October 18, 2012
7. Mattson DH, Lisak RP, Jones DE, **Corboy JR**. The American Academy of Neurology's top five Choosing Wisely recommendations. *Neurology*. 2013 Sep 10;81(11):1022-3. doi: 10.1212/WNL.0b013e3182a69c98.
8. Corboy JR June 27, 2017. Neurology Times Interview: Medication Discontinuation in Patients With Multiple Sclerosis: A Conversation With John R. Corboy, MD

Trainees:

1. Hanna Kraus Summer research in lab, neurovirology, 1999
2. Mario Carmosino Summer research project, Initial evaluations for multiple sclerosis in a university multiple sclerosis center: Outcomes and the role of magnetic resonance imaging in referral, 2002. Received Research award at School of Medicine Commencement, 2005. See references above.
3. Karen Rollins Multiple Sclerosis clinical fellow, 7/1/2004-6/30/2005
4. Kristen Graesser Multiple Sclerosis clinical fellow, 7/1/2007-6/30/2008
5. Jeffrey Hebert, PT, PhD Doctoral Dissertation 2009-2012
6. Matthew West Multiple Sclerosis clinical fellow, 7/1/2010-6/30/2011
7. Teri Schreiner Multiple Sclerosis clinical fellow, 7/1/2011-6/30/2012
8. Mira Estin MSTP 2012-2017
9. Julie Seibert, MD MS/Neuroimmunology clinical fellow 4/1/2014-3/31/2015
10. Daniel Smith, MD, Neuro-Infection/Neuroimmunology Fellow 2015-2016
11. Siamac Esfandi, MD MS/Neuroimmunology Clinical fellow 2016-2017
12. Lindsay Horton, MD, MS/NI fellow 2017-2019
13. Murtaza Khan, MD Neuro-Infection/Neuroimmunology Fellow 2017-2018
14. Krzysztof Romanowski, MD, MS/Neuroimmunology Fellow 2018-2019

15. Christine Gill, MD, Neuro-Infection/Neuroimmunology Fellow 2018-2019